A new study shows that when Faro’s Study Designer Tool was applied to clinical trial protocol development, it was easy to visualize, quantify, and therefore recommend, trial improvements.
While SaaS technologies have been integral to clinical development processes, their adoption continues to pose challenges across Pharma and Biotech
Faro Health Inc. is pleased to announce the appointment of Vivian DeWoskin as Chief Strategy Officer.
By leveraging data and analytics in protocol design, Faro Health CEO Dr Scott Chetham argues, sponsors can unlock automation, make data-driven decisions, and reduce patient burden.
Faro Health’s Study Designer streamlines the development of clinical protocols by overcoming inefficiencies in traditional processes, enabling clinical scientists to optimize their work and better serve stakeholders and patients.
This webinar will provide a clear framework and methodology to optimize the design of clinical trials to achieve key outcomes in resource-constrained environments.
Faro Health Inc. is pleased to announce the appointment of Vivian DeWoskin as Chief Strategy Officer.
